Bard Decision Unlikely To Deter DoJ From Seeking Criminal Prosecution
This article was originally published in The Gray Sheet
Executive Summary
The Justice Department will continue to prosecute medical device companies and executives suspected of intentionally violating FDA regulations, despite the department's disappointment with the outcome of its case against C.R. Bard.
You may also be interested in...
Gliatech Weighing Adcon Sale, Bankruptcy Filing; DoJ Makes Example Of Firm
Gliatech is considering the sale of its flagship Adcon anti-adhesion technology and filing for bankruptcy following a recent settlement with the Department of Justice due to failure to supply required information to FDA
Gliatech Weighing Adcon Sale, Bankruptcy Filing; DoJ Makes Example Of Firm
Gliatech is considering the sale of its flagship Adcon anti-adhesion technology and filing for bankruptcy following a recent settlement with the Department of Justice due to failure to supply required information to FDA
Ex-Bard execs' trial: jury convicts Leichter, Cvinar, Prigmore, acquits Maloney, Thurston.
EX-BARD EXECS' TRIAL: JURY'S SPLIT DECISION appears to reflect the executives' varying levels of decision-making authority over the unlawful activities at the USCI division. The jury convicted Lee Leichter, John Cvinar, and David Prigmore of charges that they conspired to defraud FDA in connection with the sales and distribution of heart catheters. George Maloney and Kenneth Thurston were both acquitted of the charge.